Table of Content

1 Peptide Cancer Vaccine Market Overview
1.1 Peptide Cancer Vaccine Product Scope
1.2 Peptide Cancer Vaccine Segment by Regions
1.2.1 Global Peptide Cancer Vaccine Sales by Regions (2016 & 2021 & 2027)
1.2.2 USA
1.2.3 Europe
1.2.4 Japan
1.2.5 China
1.2.6 South America
1.2.7 Other
1.3 Peptide Cancer Vaccine Segment by Application
1.3.1 Global Peptide Cancer Vaccine Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Peptide Cancer Vaccine Market Estimates and Forecasts (2016-2027)
1.4.1 Global Peptide Cancer Vaccine Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Peptide Cancer Vaccine Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Peptide Cancer Vaccine Price Trends (2016-2027)

2 Peptide Cancer Vaccine Estimates and Forecasts by Region
2.1 Global Peptide Cancer Vaccine Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Peptide Cancer Vaccine Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Peptide Cancer Vaccine Sales Market Share by Region (2016-2021)
2.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Region (2016-2021)
2.3 Global Peptide Cancer Vaccine Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Peptide Cancer Vaccine Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Peptide Cancer Vaccine Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Peptide Cancer Vaccine Estimates and Projections (2016-2027)
2.4.2 Europe Peptide Cancer Vaccine Estimates and Projections (2016-2027)
2.4.3 China Peptide Cancer Vaccine Estimates and Projections (2016-2027)
2.4.4 Japan Peptide Cancer Vaccine Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Peptide Cancer Vaccine Estimates and Projections (2016-2027)
2.4.6 India Peptide Cancer Vaccine Estimates and Projections (2016-2027)
3 Global Peptide Cancer Vaccine Competition Landscape by Players
3.1 Global Top Peptide Cancer Vaccine Players by Sales (2016-2021)
3.2 Global Top Peptide Cancer Vaccine Players by Revenue (2016-2021)
3.3 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2020)
3.4 Global Peptide Cancer Vaccine Average Price by Company (2016-2021)
3.5 Manufacturers Peptide Cancer Vaccine Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Peptide Cancer Vaccine Market Size by Regions
4.1 Global Peptide Cancer Vaccine Historic Market Review by Regions (2016-2021)
4.1.1 Global Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
4.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Regions (2016-2021)
4.1.3 Global Peptide Cancer Vaccine Price by Regions (2016-2021)
4.2 Global Peptide Cancer Vaccine Market Estimates and Forecasts by Regions (2022-2027)
4.2.1 Global Peptide Cancer Vaccine Sales Forecast by Regions (2022-2027)
4.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Regions (2022-2027)
4.2.3 Global Peptide Cancer Vaccine Price Forecast by Regions (2022-2027)
5 Global Peptide Cancer Vaccine Market Size by Application
5.1 Global Peptide Cancer Vaccine Historic Market Review by Application (2016-2021)
5.1.1 Global Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
5.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Application (2016-2021)
5.1.3 Global Peptide Cancer Vaccine Price by Application (2016-2021)
5.2 Global Peptide Cancer Vaccine Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Peptide Cancer Vaccine Sales Forecast by Application (2022-2027)
5.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2022-2027)
5.2.3 Global Peptide Cancer Vaccine Price Forecast by Application (2022-2027)

6 North America Peptide Cancer Vaccine Market Facts & Figures
6.1 North America Peptide Cancer Vaccine Sales by Company
6.1.1 North America Peptide Cancer Vaccine Sales by Company (2016-2021)
6.1.2 North America Peptide Cancer Vaccine Revenue by Company (2016-2021)
6.2 North America Peptide Cancer Vaccine Sales Breakdown by Regions
6.2.1 North America Peptide Cancer Vaccine Sales Breakdown by Regions (2016-2021)
6.2.2 North America Peptide Cancer Vaccine Sales Breakdown by Regions (2022-2027)
6.3 North America Peptide Cancer Vaccine Sales Breakdown by Application
6.3.1 North America Peptide Cancer Vaccine Sales Breakdown by Application (2016-2021)
6.3.2 North America Peptide Cancer Vaccine Sales Breakdown by Application (2022-2027)

7 Europe Peptide Cancer Vaccine Market Facts & Figures
7.1 Europe Peptide Cancer Vaccine Sales by Company
7.1.1 Europe Peptide Cancer Vaccine Sales by Company (2016-2021)
7.1.2 Europe Peptide Cancer Vaccine Revenue by Company (2016-2021)
7.2 Europe Peptide Cancer Vaccine Sales Breakdown by Regions
7.2.1 Europe Peptide Cancer Vaccine Sales Breakdown by Regions (2016-2021)
7.2.2 Europe Peptide Cancer Vaccine Sales Breakdown by Regions (2022-2027)
7.3 Europe Peptide Cancer Vaccine Sales Breakdown by Application
7.3.1 Europe 146 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 146 Sales Breakdown by Application (2022-2027)

8 China Peptide Cancer Vaccine Market Facts & Figures
8.1 China Peptide Cancer Vaccine Sales by Company
8.1.1 China Peptide Cancer Vaccine Sales by Company (2016-2021)
8.1.2 China Peptide Cancer Vaccine Revenue by Company (2016-2021)
8.2 China Peptide Cancer Vaccine Sales Breakdown by Regions
8.2.1 China Peptide Cancer Vaccine Sales Breakdown by Regions (2016-2021)
8.2.2 China Peptide Cancer Vaccine Sales Breakdown by Regions (2022-2027)
8.3 China Peptide Cancer Vaccine Sales Breakdown by Application
8.3.1 China 314 Sales Breakdown by Application (2016-2021)
8.3.2 China 314 Sales Breakdown by Application (2022-2027)

9 Japan Peptide Cancer Vaccine Market Facts & Figures
9.1 Japan Peptide Cancer Vaccine Sales by Company
9.1.1 Japan Peptide Cancer Vaccine Sales by Company (2016-2021)
9.1.2 Japan Peptide Cancer Vaccine Revenue by Company (2016-2021)
9.2 Japan Peptide Cancer Vaccine Sales Breakdown by Regions
9.2.1 Japan Peptide Cancer Vaccine Sales Breakdown by Regions (2016-2021)
9.2.2 Japan Peptide Cancer Vaccine Sales Breakdown by Regions (2022-2027)
9.3 Japan Peptide Cancer Vaccine Sales Breakdown by Application
9.3.1 Japan Jan. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Jan. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Peptide Cancer Vaccine Market Facts & Figures
10.1 Southeast Asia Peptide Cancer Vaccine Sales by Company
10.1.1 Southeast Asia Peptide Cancer Vaccine Sales by Company (2016-2021)
10.1.2 Southeast Asia Peptide Cancer Vaccine Revenue by Company (2016-2021)
10.2 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Regions
10.2.1 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Regions (2016-2021)
10.2.2 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Regions (2022-2027)
10.3 Southeast Asia Peptide Cancer Vaccine Sales Breakdown by Application
10.3.1 Southeast Asia K Doses Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Doses Sales Breakdown by Application (2022-2027)

11 India Peptide Cancer Vaccine Market Facts & Figures
11.1 India Peptide Cancer Vaccine Sales by Company
11.1.1 India Peptide Cancer Vaccine Sales by Company (2016-2021)
11.1.2 India Peptide Cancer Vaccine Revenue by Company (2016-2021)
11.2 India Peptide Cancer Vaccine Sales Breakdown by Regions
11.2.1 India Peptide Cancer Vaccine Sales Breakdown by Regions (2016-2021)
11.2.2 India Peptide Cancer Vaccine Sales Breakdown by Regions (2022-2027)
11.3 India Peptide Cancer Vaccine Sales Breakdown by Application
11.3.1 India Peptide Cancer Vaccine Sales Breakdown by Application (2016-2021)
11.3.2 India Peptide Cancer Vaccine Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Peptide Cancer Vaccine Business
12.1 TapImmune
12.1.1 TapImmune Corporation Information
12.1.2 TapImmune Business Overview
12.1.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.1.4 TapImmune Peptide Cancer Vaccine Products Offered
12.1.5 TapImmune Recent Development
12.2 BrightPath Biotherapeutics
12.2.1 BrightPath Biotherapeutics Corporation Information
12.2.2 BrightPath Biotherapeutics Business Overview
12.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.2.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
12.2.5 BrightPath Biotherapeutics Recent Development
12.3 Ultimovacs
12.3.1 Ultimovacs Corporation Information
12.3.2 Ultimovacs Business Overview
12.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Ultimovacs Peptide Cancer Vaccine Products Offered
12.3.5 Ultimovacs Recent Development
12.4 Sellas
12.4.1 Sellas Corporation Information
12.4.2 Sellas Business Overview
12.4.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Sellas Peptide Cancer Vaccine Products Offered
12.4.5 Sellas Recent Development
12.5 Boston Biomedical
12.5.1 Boston Biomedical Corporation Information
12.5.2 Boston Biomedical Business Overview
12.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Boston Biomedical Peptide Cancer Vaccine Products Offered
12.5.5 Boston Biomedical Recent Development
12.6 Imugene
12.6.1 Imugene Corporation Information
12.6.2 Imugene Business Overview
12.6.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Imugene Peptide Cancer Vaccine Products Offered
12.6.5 Imugene Recent Development
12.7 VAXON Biotech
12.7.1 VAXON Biotech Corporation Information
12.7.2 VAXON Biotech Business Overview
12.7.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.7.4 VAXON Biotech Peptide Cancer Vaccine Products Offered
12.7.5 VAXON Biotech Recent Development
12.8 Generex Biotechnology
12.8.1 Generex Biotechnology Corporation Information
12.8.2 Generex Biotechnology Business Overview
12.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Generex Biotechnology Peptide Cancer Vaccine Products Offered
12.8.5 Generex Biotechnology Recent Development
12.9 OncoTherapy Science
12.9.1 OncoTherapy Science Corporation Information
12.9.2 OncoTherapy Science Business Overview
12.9.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.9.4 OncoTherapy Science Peptide Cancer Vaccine Products Offered
12.9.5 OncoTherapy Science Recent Development
12.10 Immatics
12.10.1 Immatics Corporation Information
12.10.2 Immatics Business Overview
12.10.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Immatics Peptide Cancer Vaccine Products Offered
12.10.5 Immatics Recent Development
12.11 ISA Pharmaceuticals
12.11.1 ISA Pharmaceuticals Corporation Information
12.11.2 ISA Pharmaceuticals Business Overview
12.11.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
12.11.4 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
12.11.5 ISA Pharmaceuticals Recent Development

13 Peptide Cancer Vaccine Manufacturing Cost Analysis
13.1 Peptide Cancer Vaccine Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
13.4 Peptide Cancer Vaccine Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Peptide Cancer Vaccine Distributors List
14.3 Peptide Cancer Vaccine Customers

15 Market Dynamics
15.1 Peptide Cancer Vaccine Market Trends
15.2 Peptide Cancer Vaccine Drivers
15.3 Peptide Cancer Vaccine Market Challenges
15.4 Peptide Cancer Vaccine Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Peptide Cancer Vaccine Sales (US$ Million) Growth Rate by Regions (2016 & 2021 & 2027)
Table 2. Global Peptide Cancer Vaccine Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Peptide Cancer Vaccine Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Peptide Cancer Vaccine Sales (K Doses) by Region (2016-2021)
Table 5. Global Peptide Cancer Vaccine Sales Market Share by Region (2016-2021)
Table 6. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Peptide Cancer Vaccine Revenue Share by Region (2016-2021)
Table 8. Global Peptide Cancer Vaccine Sales (K Doses) Forecast by Region (2022-2027)
Table 9. Global Peptide Cancer Vaccine Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Peptide Cancer Vaccine Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Peptide Cancer Vaccine Revenue Share Forecast by Region (2022-2027)
Table 12. Global Peptide Cancer Vaccine Sales (K Doses) of Key Companies (2016-2021)
Table 13. Global Peptide Cancer Vaccine Sales Share by Company (2016-2021)
Table 14. Global Peptide Cancer Vaccine Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Peptide Cancer Vaccine Revenue Share by Company (2016-2021)
Table 16. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Cancer Vaccine as of 2020)
Table 17. Global Peptide Cancer Vaccine Average Price (USD/Dose) of Key Company (2016-2021)
Table 18. Manufacturers Peptide Cancer Vaccine Manufacturing Sites and Area Served
Table 19. Manufacturers Peptide Cancer Vaccine Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Peptide Cancer Vaccine Sales (K Doses) by Regions (2016-2021)
Table 22. Global Peptide Cancer Vaccine Sales Share by Regions (2016-2021)
Table 23. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Regions (2016-2021)
Table 24. Global Peptide Cancer Vaccine Price (USD/Dose) by Regions (2016-2021)
Table 25. Global Peptide Cancer Vaccine Sales Share by Regions (2022-2027)
Table 26. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Regions (2022-2027)
Table 27. Global Peptide Cancer Vaccine Revenue Share by Regions (2022-2027)
Table 28. Global Peptide Cancer Vaccine Price (USD/Dose) by Regions (2022-2027)
Table 29. Global Peptide Cancer Vaccine Sales (K Doses) by Application (2016-2021)
Table 30. Global Peptide Cancer Vaccine Sales Share by Application (2016-2021)
Table 31. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Peptide Cancer Vaccine Price (USD/Dose) by Application (2016-2021)
Table 33. Global Peptide Cancer Vaccine Sales (K Doses) by Application (2022-2027)
Table 34. Global Peptide Cancer Vaccine Sales Share by Application (2022-2027)
Table 35. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Peptide Cancer Vaccine Revenue Share by Application (2022-2027)
Table 37. Global Peptide Cancer Vaccine Price (USD/Dose) by Application (2022-2027)
Table 38. North America Peptide Cancer Vaccine Sales (K Doses) by Company (2016-2021)
Table 39. North America Peptide Cancer Vaccine Sales Market Share by Company (2016-2021)
Table 40. North America Peptide Cancer Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Peptide Cancer Vaccine Revenue Market Share by Company (2016-2021)
Table 42. North America Peptide Cancer Vaccine Sales by Regions (2016-2021) & (K Doses)
Table 43. North America Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Table 44. North America Peptide Cancer Vaccine Sales by Regions (2022-2027) & (K Doses)
Table 45. North America Peptide Cancer Vaccine Sales Market Share by Regions (2022-2027)
Table 46. North America Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 47. North America Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 48. North America Peptide Cancer Vaccine Sales by Application (2022-2027) & (K Doses)
Table 49. North America Peptide Cancer Vaccine Sales Market Share by Application (2022-2027)
Table 50. Europe Peptide Cancer Vaccine Sales (K Doses) by Company (2016-2021)
Table 51. Europe Peptide Cancer Vaccine Sales Market Share by Company (2016-2021)
Table 52. Europe Peptide Cancer Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Peptide Cancer Vaccine Revenue Market Share by Company (2016-2021)
Table 54. Europe Peptide Cancer Vaccine Sales by Regions (2016-2021) & (K Doses)
Table 55. Europe Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Table 56. Europe Peptide Cancer Vaccine Sales by Regions (2022-2027) & (K Doses)
Table 57. Europe Peptide Cancer Vaccine Sales Market Share by Regions (2022-2027)
Table 58. Europe Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 59. Europe Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 60. Europe Peptide Cancer Vaccine Sales by Application (2022-2027) & (K Doses)
Table 61. Europe Peptide Cancer Vaccine Sales Market Share by Application (2022-2027)
Table 62. China Peptide Cancer Vaccine Sales (K Doses) by Company (2016-2021)
Table 63. China Peptide Cancer Vaccine Sales Market Share by Company (2016-2021)
Table 64. China Peptide Cancer Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Peptide Cancer Vaccine Revenue Market Share by Company (2016-2021)
Table 66. China Peptide Cancer Vaccine Sales by Regions (2016-2021) & (K Doses)
Table 67. China Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Table 68. China Peptide Cancer Vaccine Sales by Regions (2022-2027) & (K Doses)
Table 69. China Peptide Cancer Vaccine Sales Market Share by Regions (2022-2027)
Table 70. China Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 71. China Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 72. China Peptide Cancer Vaccine Sales by Application (2022-2027) & (K Doses)
Table 73. China Peptide Cancer Vaccine Sales Market Share by Application (2022-2027)
Table 74. Japan Peptide Cancer Vaccine Sales (K Doses) by Company (2016-2021)
Table 75. Japan Peptide Cancer Vaccine Sales Market Share by Company (2016-2021)
Table 76. Japan Peptide Cancer Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Peptide Cancer Vaccine Revenue Market Share by Company (2016-2021)
Table 78. Japan Peptide Cancer Vaccine Sales by Regions (2016-2021) & (K Doses)
Table 79. Japan Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Table 80. Japan Peptide Cancer Vaccine Sales by Regions (2022-2027) & (K Doses)
Table 81. Japan Peptide Cancer Vaccine Sales Market Share by Regions (2022-2027)
Table 82. Japan Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 83. Japan Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 84. Japan Peptide Cancer Vaccine Sales by Application (2022-2027) & (K Doses)
Table 85. Japan Peptide Cancer Vaccine Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Peptide Cancer Vaccine Sales (K Doses) by Company (2016-2021)
Table 87. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Peptide Cancer Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Peptide Cancer Vaccine Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Peptide Cancer Vaccine Sales by Regions (2016-2021) & (K Doses)
Table 91. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Table 92. Southeast Asia Peptide Cancer Vaccine Sales by Regions (2022-2027) & (K Doses)
Table 93. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Regions (2022-2027)
Table 94. Southeast Asia Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 95. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Peptide Cancer Vaccine Sales by Application (2022-2027) & (K Doses)
Table 97. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Application (2022-2027)
Table 98. India Peptide Cancer Vaccine Sales (K Doses) by Company (2016-2021)
Table 99. India Peptide Cancer Vaccine Sales Market Share by Company (2016-2021)
Table 100. India Peptide Cancer Vaccine Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Peptide Cancer Vaccine Revenue Market Share by Company (2016-2021)
Table 102. India Peptide Cancer Vaccine Sales by Regions (2016-2021) & (K Doses)
Table 103. India Peptide Cancer Vaccine Sales Market Share by Regions (2016-2021)
Table 104. India Peptide Cancer Vaccine Sales by Regions (2022-2027) & (K Doses)
Table 105. India Peptide Cancer Vaccine Sales Market Share by Regions (2022-2027)
Table 106. India Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 107. India Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Table 108. India Peptide Cancer Vaccine Sales by Application (2022-2027) & (K Doses)
Table 109. India Peptide Cancer Vaccine Sales Market Share by Application (2022-2027)
Table 110. TapImmune Corporation Information
Table 111. TapImmune Description and Business Overview
Table 112. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 113. TapImmune Peptide Cancer Vaccine Product
Table 114. TapImmune Recent Development
Table 115. BrightPath Biotherapeutics Corporation Information
Table 116. BrightPath Biotherapeutics Description and Business Overview
Table 117. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 118. BrightPath Biotherapeutics Peptide Cancer Vaccine Product
Table 119. BrightPath Biotherapeutics Recent Development
Table 120. Ultimovacs Corporation Information
Table 121. Ultimovacs Description and Business Overview
Table 122. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 123. Ultimovacs Peptide Cancer Vaccine Product
Table 124. Ultimovacs Recent Development
Table 125. Sellas Corporation Information
Table 126. Sellas Description and Business Overview
Table 127. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 128. Sellas Peptide Cancer Vaccine Product
Table 129. Sellas Recent Development
Table 130. Boston Biomedical Corporation Information
Table 131. Boston Biomedical Description and Business Overview
Table 132. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 133. Boston Biomedical Peptide Cancer Vaccine Product
Table 134. Boston Biomedical Recent Development
Table 135. Imugene Corporation Information
Table 136. Imugene Description and Business Overview
Table 137. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 138. Imugene Peptide Cancer Vaccine Product
Table 139. Imugene Recent Development
Table 140. VAXON Biotech Corporation Information
Table 141. VAXON Biotech Description and Business Overview
Table 142. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 143. VAXON Biotech Peptide Cancer Vaccine Product
Table 144. VAXON Biotech Recent Development
Table 145. Generex Biotechnology Corporation Information
Table 146. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 147. Generex Biotechnology Description and Business Overview
Table 148. Generex Biotechnology Peptide Cancer Vaccine Product
Table 149. Generex Biotechnology Recent Development
Table 150. OncoTherapy Science Corporation Information
Table 151. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 152. OncoTherapy Science Description and Business Overview
Table 153. OncoTherapy Science Peptide Cancer Vaccine Product
Table 154. OncoTherapy Science Recent Development
Table 155. Immatics Corporation Information
Table 156. Immatics Description and Business Overview
Table 157. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 158. Immatics Peptide Cancer Vaccine Product
Table 159. Immatics Recent Development
Table 160. ISA Pharmaceuticals Corporation Information
Table 161. ISA Pharmaceuticals Description and Business Overview
Table 162. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2016-2021)
Table 163. ISA Pharmaceuticals Peptide Cancer Vaccine Product
Table 164. ISA Pharmaceuticals Recent Development
Table 165. Production Base and Market Concentration Rate of Raw Material
Table 166. Key Suppliers of Raw Materials
Table 167. Peptide Cancer Vaccine Distributors List
Table 168. Peptide Cancer Vaccine Customers List
Table 169. Peptide Cancer Vaccine Market Trends
Table 170. Peptide Cancer Vaccine Market Drivers
Table 171. Peptide Cancer Vaccine Market Challenges
Table 172. Peptide Cancer Vaccine Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Sales Market Share by Regions in 2021 & 2027
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Peptide Cancer Vaccine Sales Market Share by Application in 2021 & 2027
Figure 6. Breast Cancer Examples
Figure 7. Lung Cancer Examples
Figure 8. Melanoma Examples
Figure 9. Prostate Cancer Examples
Figure 10. Others Examples
Figure 11. Global Peptide Cancer Vaccine Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Peptide Cancer Vaccine Sales Growth Rate (2016-2027) & (US$ Million)
Figure 13. Global Peptide Cancer Vaccine Sales (K Doses) Growth Rate (2016-2027)
Figure 14. Global Peptide Cancer Vaccine Price Trends Growth Rate (2016-2027) (USD/Dose)
Figure 15. Global Peptide Cancer Vaccine Revenue Market Share by Region: 2016 VS 2021
Figure 16. Global Peptide Cancer Vaccine Revenue Market Share by Region: 2021 VS 2027
Figure 17. North America Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 18. North America Peptide Cancer Vaccine Sales (K Doses) Growth Rate (2016-2027)
Figure 19. Europe Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. Europe Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 21. China Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. China Peptide Cancer Vaccine Sales (Million USD) and Growth Rate (2016-2027)
Figure 23. Japan Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. Japan Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 25. Southeast Asia Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. Southeast Asia Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 27. India Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2016-2027)
Figure 28. India Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2016-2027)
Figure 29. Global 5 Largest Peptide Cancer Vaccine Players Market Share by Revenue in Peptide Cancer Vaccine: 2016 & 2020
Figure 30. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 31. Global Peptide Cancer Vaccine Revenue Share by Regions (2016-2021)
Figure 32. Global Peptide Cancer Vaccine Revenue Growth Rate by Regions in 2016 & 2020
Figure 33. Global Peptide Cancer Vaccine Revenue Share by Application (2016-2021)
Figure 34. Global Peptide Cancer Vaccine Revenue Growth Rate by Application in 2016 & 2020
Figure 35. North America Peptide Cancer Vaccine Sales Market Share by Regions in 2020
Figure 36. North America Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 37. Europe Peptide Cancer Vaccine Sales Market Share by Regions in 2020
Figure 38. Europe Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 39. China Peptide Cancer Vaccine Sales Market Share by Regions in 2020
Figure 40. China Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 41. Japan Peptide Cancer Vaccine Sales Market Share by Regions in 2020
Figure 42. Japan Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 43. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Regions in 2020
Figure 44. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 45. India Peptide Cancer Vaccine Sales Market Share by Regions in 2020
Figure 46. India Peptide Cancer Vaccine Sales Market Share by Application in 2020
Figure 47. Key Raw Materials Price Trend
Figure 48. Manufacturing Cost Structure of Peptide Cancer Vaccine
Figure 49. Manufacturing Process Analysis of Peptide Cancer Vaccine
Figure 50. Peptide Cancer Vaccine Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed